Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 38

Sort by

Sort Order Select

Journal Articles

Systematic Review and Meta-Analysis of Spleen Volume Reduction and Overall Survival in Myelofibrosis Patients Treated with JAK-Inhibitors

Dahniel L Sastow, Hannah Goulart, Karen Bedirian, Madhu Mazumdar, Lily Martin, Kyle Farina, John O. Mascarenhas, Douglas Tremblay

Blood (2024) 144 (Supplement 1): 6665.

https://doi.org/10.1182/blood-2024-200228

Published: 2024

Journal Articles

Early Anemia Response in Patients with Myelofibrosis Treated with Pacritinib in Real-Word Clinical Settings

John O. Mascarenhas, Michael Marrone, Lisa Morere, Abiola Oladapo, Purvi Suthar, Teena Sura, Anupama Vasudevan, Michael Vredenburg, Jia Zeng, Raajit Rampal

Blood (2024) 144 (Supplement 1): 6650.

https://doi.org/10.1182/blood-2024-210598

Published: 2024

Journal Articles

POIESIS: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Global Phase 3 Study of Navtemadlin As Add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients with Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib

Pankit Vachhani, Raajit Rampal, Terrence Bradley, Claire Harrison, Tania Jain, Andrew T. Kuykendall, Francesca Palandri, John O. Mascarenhas, Haifa Kathrin Al-Ali, Francesco Passamonti, Anna Nekhymchuk, Hilarie Foss, Wayne Rothbaum, Srdan Verstovsek, Florian Heidel

Blood (2024) 144 (Supplement 1): 1808.2.

https://doi.org/10.1182/blood-2024-200966

Published: 2024

Journal Articles

Imetelstat Versus Best Available Therapy in Patients with Intermediate-2 or High-Risk Myelofibrosis Relapsed or Refractory to Janus Kinase Inhibitor in IMpactMF, a Randomized, Open-Label, Phase 3 Trial

John O. Mascarenhas, Claire Harrison, Prithviraj Bose, Jean-Jacques Kiladjian, Alessandro Lucchesi, Alessandro Maria Vannucchi, Tymara Berry, Jennifer Riggs, Lixian Peng, Fei Huang, Ying Wan, Vivian Rodolf, Judy Ho, Shyamala Navada, Rami S. Komrokji

Blood (2024) 144 (Supplement 1): 1808.1.

https://doi.org/10.1182/blood-2024-199235

Published: 2024

Journal Articles

A Multicenter, Open-Label, Phase 1 Clinical Trial of AJ1-11095 Administered As Oral Monotherapy in Patients with Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), or Post-Essential Thrombocythemia Myelofibrosis (PET-MF) Who Have Been Failed By a Type I JAK2 Inhibitor (JAK2i)

John O. Mascarenhas, Uma Borate, Prithviraj Bose, John C. Byrd, Jacqueline S. Garcia, Michael R. Grunwald, Gabriela S. Hobbs, Ronald Hoffman, Andrew T. Kuykendall, Ruben A. Mesa, Stephen Oh, Raajit Rampal, Abdulraheem Yacoub, David P. Steensma

Blood (2024) 144 (Supplement 1): 3147.1.

https://doi.org/10.1182/blood-2024-193905

Published: 2024

Journal Articles

HOPE-PMF: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study to Assess Efficacy and Safety of Ropeginterferon Alfa-2b in Patients with Early/Lower-Risk Primary Myelofibrosis

Ghaith Abu-Zeinah, Albert Qin, Harinder Gill, Norio Komatsu, John O. Mascarenhas, Weichung Joe Shih, Oleh Zagrijtschuk, Toshiaki Sato, Kazuya Shimoda, Richard T. Silver, Ruben A. Mesa

Blood (2024) 144 (Supplement 1): 3191.1.

https://doi.org/10.1182/blood-2024-200319

Published: 2024

Journal Articles

New Criteria for Evaluating Outcomes of Myelofibrosis Therapy

Monia Marchetti, Alessandro Maria Vannucchi, John O. Mascarenhas, Alberto Alvarez-Larran, Prithviraj Bose, Robert Peter Gale, Claire Harrison, Rüdiger Hehlmann, Jean-Jacques Kiladjian, Steffen Koschmieder, Ruben Mesa, Francesco Passamonti, Alessandro Rambaldi, Ayalew Tefferi, Tiziano Barbui

Blood (2024) 144 (Supplement 1): 7898.

https://doi.org/10.1182/blood-2024-198646

Published: 2024

Journal Articles

Acute Promyelocytic Leukemia in the Molecular Age

Navin Bhatt, Michelle Becker, Juana Martinez, Hannah Levavi, Kyle Farina, Marina Kremyanskaya, Bridget Kelly Marcellino, Alan Shih, Lewis R. Silverman, Vesna Najfeld, John O. Mascarenhas, Douglas Tremblay, Jonathan Feld

Blood (2024) 144 (Supplement 1): 6131.

https://doi.org/10.1182/blood-2024-211957

Published: 2024

Journal Articles

Updated Results from the Phase 3 Manifest-2 Study of Pelabresib in Combination with Ruxolitinib for Janus Kinase Inhibitor-Naïve Patients with Myelofibrosis

Blood (2024) 144 (Supplement 1): 3178.

https://doi.org/10.1182/blood-2024-193193

Published: 2024

Journal Articles

Results from the Randomized, Multicenter, Global Phase 3 BOREAS Study: Navtemadlin Versus Best Available Therapy in JAK Inhibitor Relapsed / Refractory Myelofibrosis

John O. Mascarenhas, Viola Maria Popov, Sanjay Mohan, Zübeyde Nur Özkurt, Jean-Jacques Kiladjian, Haifa Kathrin Al-Ali, Andrew Perkins, Zhuying Huang, Hope Qamoos, Jesse McGreivy, Wayne Rothbaum, Srdan Verstovsek, Maciej Kaźmierczak

Blood (2024) 144 (Supplement 1): 1000.

https://doi.org/10.1182/blood-2024-201642

Published: 2024

Journal Articles

Trial Update from IMproveMF, an Ongoing, Open-Label, Dose-Escalation and -Expansion, Phase 1/1B Trial to Evaluate the Safety, Pharmacokinetics, and Clinical Activity of the Novel Combination of Imetelstat with Ruxolitinib in Patients with Intermediate-1, Intermediate-2, or High-Risk Myelofibrosis (MF)

John O. Mascarenhas, Salman Otoukesh, Terrence Bradley, Bart L. Scott, Habte A. Yimer, Souria Dougherty, Lixian Peng, Fei Huang, Ying Wan, Faye M. Feller, Vivian Rodolf, Judy Ho, Tymara Berry, Andrew T. Kuykendall

Blood (2024) 144 (Supplement 1): 998.

https://doi.org/10.1182/blood-2024-203800

Published: 2024

Journal Articles

Disease-Modifying Activity of Navtemadlin Correlates with Clinical Responses in a Randomized, Multicenter, Global Phase 3 Study (BOREAS) in JAK-Inhibitor Relapsed/Refractory Myelofibrosis

John O. Mascarenhas, Prithviraj Bose, Hsin-An Hou, Wojciech Homenda, David Ross, Sanjay R Mohan, Jean-Jacques Kiladjian, Haifa Kathrin Al-Ali, Andrew Perkins, Yulia Khalina, Tracy Clevenger, Zhuying Huang, Jesse McGreivy, Wayne Rothbaum, Srdan Verstovsek, Alessandro M. Vannucchi

Blood (2024) 144 (Supplement 1): 483.

https://doi.org/10.1182/blood-2024-205937

Published: 2024

Journal Articles

Real-Word Effectiveness of Pacritinib in Patients with Myelofibrosis Who Have Thrombocytopenia and Anemia

Raajit Rampal, Michael Marrone, Lisa Morere, Abiola Oladapo, Purvi Suthar, Teena Sura, Anupama Vasudevan, Michael Vredenburg, Jia Zeng, John O. Mascarenhas

Blood (2024) 144 (Supplement 1): 6649.

https://doi.org/10.1182/blood-2024-210274

Published: 2024

Journal Articles

A Novel Three-Way Translocation Involving ETV6-IL3 Drives AML with Eosinophilia

Ariel Siegel, Joseph Tripodi, Brianna Kelly, Sebastian Elghaity-Beckley, Michelle Becker, Douglas Tremblay, Jonathan Feld, Hannah Levavi, Marina Kremyanskaya, Bridget Kelly Marcellino, Christian Salib, Alla Keyzner, Amy Duffield, John O. Mascarenhas, Vesna Najfeld, Alan Shih

Blood (2024) 144 (Supplement 1): 6098.

https://doi.org/10.1182/blood-2024-203588

Published: 2024

Journal Articles

A Phase 1/2 Study of Nuvisertib (TP-3654), an Investigational Selective PIM1 Kinase Inhibitor, in Combination with JAK Inhibitors Ruxolitinib or Momelotinib in Patients with Myelofibrosis

Blood (2024) 144 (Supplement 1): 6629.

https://doi.org/10.1182/blood-2024-200268

Published: 2024

Journal Articles

Hematologic Improvement Experienced By Pacritinib-Treated Patients with Myelofibrosis in Real-World Clinical Settings

Michael Marrone, Lisa Morere, Abiola Oladapo, Purvi Suthar, Teena Sura, Anupama Vasudevan, Michael Vredenburg, Jia Zeng, Raajit Rampal, John O. Mascarenhas

Blood (2024) 144 (Supplement 1): 3814.

https://doi.org/10.1182/blood-2024-210826

Published: 2024

Journal Articles

Clinical and Molecular Characterization of Disease Progression in Patients (Pts) with Low-Risk Myelofibrosis (MF) Enrolled in the MOST Study

Abdulraheem Yacoub, Ellen K. Ritchie, Naveen Pemmaraju, Richard Zuniga, Erin L. Crowgey, Cynthia Timmers, Patricia Feldman, J.E. Hamer-Maansson, Tricia Kalafut, Evan M. Braunstein, John O. Mascarenhas

Blood (2024) 144 (Supplement 1): 3136.

https://doi.org/10.1182/blood-2024-199810

Published: 2024

Journal Articles

Improvement in Serum Albumin As a Measure of Improved Metabolic Profile in Pacritinib-Treated Patients: A Retrospective Analysis of Patients Treated across Three Clinical Trials

Francesca Palandri, Marta Sobas, Claire Harrison, Raajit Rampal, Sarah Buckley, Purvi Suthar, Karisse Roman-Torres, John O. Mascarenhas

Blood (2024) 144 (Supplement 1): 3191.

https://doi.org/10.1182/blood-2024-192908

Published: 2024

Journal Articles

TP53 Alterations Confer Increased Risk of Leukemic Transformation and Worse Survival As Compared to High Molecular Risk Mutations in Patients with Myeloproliferative Neoplasms

Blood (2024) 144 (Supplement 1): 243.

https://doi.org/10.1182/blood-2024-206688

Published: 2024

Journal Articles

Relative Influence of Socioeconomic and Biological Determinants of Outcomes in Adult Acute Lymphoblastic Leukemia

Juana Martinez, Michelle Becker, Megan Metzger, Nagma Shah, Erin Garbes Feliciano, Alberto Busmail Haylock, Navin Bhatt, Nikolaos Spyrou, John O. Mascarenhas, Douglas Tremblay, Jonathan Feld, Marina Kremyanskaya, Michal Bar-Natan, Hannah Levavi

Blood (2024) 144 (Supplement 1): 2798.

https://doi.org/10.1182/blood-2024-212243

Published: 2024

NARROW

Systematic Review and Meta-Analysis of Spleen Volume Reduction and Overall Survival in Myelofibrosis Patients Treated with JAK-Inhibitors

Early Anemia Response in Patients with Myelofibrosis Treated with Pacritinib in Real-Word Clinical Settings

POIESIS: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Global Phase 3 Study of Navtemadlin As Add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients with Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib

Imetelstat Versus Best Available Therapy in Patients with Intermediate-2 or High-Risk Myelofibrosis Relapsed or Refractory to Janus Kinase Inhibitor in IMpactMF, a Randomized, Open-Label, Phase 3 Trial

HOPE-PMF: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study to Assess Efficacy and Safety of Ropeginterferon Alfa-2b in Patients with Early/Lower-Risk Primary Myelofibrosis

New Criteria for Evaluating Outcomes of Myelofibrosis Therapy

Acute Promyelocytic Leukemia in the Molecular Age

Updated Results from the Phase 3 Manifest-2 Study of Pelabresib in Combination with Ruxolitinib for Janus Kinase Inhibitor-Naïve Patients with Myelofibrosis

Results from the Randomized, Multicenter, Global Phase 3 BOREAS Study: Navtemadlin Versus Best Available Therapy in JAK Inhibitor Relapsed / Refractory Myelofibrosis

Disease-Modifying Activity of Navtemadlin Correlates with Clinical Responses in a Randomized, Multicenter, Global Phase 3 Study (BOREAS) in JAK-Inhibitor Relapsed/Refractory Myelofibrosis

Real-Word Effectiveness of Pacritinib in Patients with Myelofibrosis Who Have Thrombocytopenia and Anemia

A Novel Three-Way Translocation Involving ETV6-IL3 Drives AML with Eosinophilia

A Phase 1/2 Study of Nuvisertib (TP-3654), an Investigational Selective PIM1 Kinase Inhibitor, in Combination with JAK Inhibitors Ruxolitinib or Momelotinib in Patients with Myelofibrosis

Hematologic Improvement Experienced By Pacritinib-Treated Patients with Myelofibrosis in Real-World Clinical Settings

Clinical and Molecular Characterization of Disease Progression in Patients (Pts) with Low-Risk Myelofibrosis (MF) Enrolled in the MOST Study

Improvement in Serum Albumin As a Measure of Improved Metabolic Profile in Pacritinib-Treated Patients: A Retrospective Analysis of Patients Treated across Three Clinical Trials

TP53 Alterations Confer Increased Risk of Leukemic Transformation and Worse Survival As Compared to High Molecular Risk Mutations in Patients with Myeloproliferative Neoplasms

Relative Influence of Socioeconomic and Biological Determinants of Outcomes in Adult Acute Lymphoblastic Leukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only